Drug Trial Radar · NCT03406780
A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy
Last checked: Nov 19, 2026Latest source record: May 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
20
Actual
Start
Apr 4, 2018
Primary completion
Mar 10, 2020
Study completion Mar 10, 2020
Sponsor
- Lead sponsor
- Capricor Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 23, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
HOPE-2 is a double-blind clinical trial evaluating the safety and efficacy of a cell therapy called CAP-1002 in study participants with Duchenne Muscular Dystrophy (DMD). Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either CAP-1002 or placebo every 3 months for a total of 4 doses during a 12-month period.
Conditions
- Muscular Dystrophies
- Muscular Dystrophy, Duchenne
- Muscular Disorders, Atrophic
- Muscular Diseases
- Neuromuscular Diseases
- Nervous System Diseases
- Genetic Diseases, X-Linked
- Genetic Diseases, Inborn
Interventions
CAP-1002Biological
The active pharmaceutical ingredient in CAP-1002 is Cardiosphere-Derived Cells (CDCs). CDCs are known to secrete numerous bioactive elements (growth factors, exosomes) which impact the therapeutic benefits of the cell-based therapy. The mechanism of action is the composite ability to be immunomodulatory, anti-fibrotic, anti-inflammatory, and pro-angiogenic.
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Functional Capacity as Assessed by the Mid-level (Elbow) Dimension Score of the Performance of Upper Limb (PUL) Version 1.2 at Month 12Time frame: Baseline, Month 12
- Number of Participants Experiencing Acute Respiratory DecompensationTime frame: Baseline through Month 12
- Number of Participants With Hypersensitivity ReactionsTime frame: Baseline through Month 12
- Number of Participants With All-cause MortalityTime frame: Baseline through Month 12
- Number of Participants With Serious Adverse Events (SAEs)Time frame: Baseline through Month 12
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) Related to Investigational Product (IP) or Administration ProcedureTime frame: Baseline through Month 12
- Number of Participants With Immune Sensitization SyndromeTime frame: Baseline through Month 12
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
University of California, Davis
Sacramento, California
Children's Hospital Colorado
Aurora, Colorado
Nemours Children's Hospital
Orlando, Florida
University of Iowa
Iowa City, Iowa
University of Massachusetts Medical Center
Worcester, Massachusetts
Washington University
St Louis, Missouri
Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio
University of Utah
Salt Lake City, Utah
Children's Hospital Wisconsin
Milwaukee, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.